9377 related articles for article (PubMed ID: 16790087)
1. The antimelanoma immunocytokine scFvMEL/TNF shows reduced toxicity and potent antitumor activity against human tumor xenografts.
Liu Y; Zhang W; Cheung LH; Niu T; Wu Q; Li C; Van Pelt CS; Rosenblum MG
Neoplasia; 2006 May; 8(5):384-93. PubMed ID: 16790087
[TBL] [Abstract][Full Text] [Related]
2. Recombinant single-chain antibody fusion construct targeting human melanoma cells and containing tumor necrosis factor.
Liu Y; Cheung LH; Marks JW; Rosenblum MG
Int J Cancer; 2004 Feb; 108(4):549-57. PubMed ID: 14696119
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic and antitumor activity of a recombinant tumor necrosis factor-B1(Fv) fusion protein on LeY antigen-expressing human cancer cells.
Scherf U; Benhar I; Webber KO; Pastan I; Brinkmann U
Clin Cancer Res; 1996 Sep; 2(9):1523-31. PubMed ID: 9816329
[TBL] [Abstract][Full Text] [Related]
4. Improved expression of a soluble single chain antibody fusion protein containing tumor necrosis factor in Escherichia coli.
Kim S; Cheung LH; Zhang W; Rosenblum MG
Appl Microbiol Biotechnol; 2007 Nov; 77(1):99-106. PubMed ID: 17703297
[TBL] [Abstract][Full Text] [Related]
5. Multi-modality therapeutics with potent anti-tumor effects: photochemical internalization enhances delivery of the fusion toxin scFvMEL/rGel.
Selbo PK; Rosenblum MG; Cheung LH; Zhang W; Berg K
PLoS One; 2009 Aug; 4(8):e6691. PubMed ID: 19690617
[TBL] [Abstract][Full Text] [Related]
6. Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus.
Gnant MF; Berger AC; Huang J; Puhlmann M; Wu PC; Merino MJ; Bartlett DL; Alexander HR; Libutti SK
Cancer Res; 1999 Sep; 59(18):4668-74. PubMed ID: 10493523
[TBL] [Abstract][Full Text] [Related]
7. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
[TBL] [Abstract][Full Text] [Related]
8. Tumor-specific Ab-mediated targeting of MHC-peptide complexes induces regression of human tumor xenografts in vivo.
Lev A; Noy R; Oved K; Novak H; Segal D; Walden P; Zehn D; Reiter Y
Proc Natl Acad Sci U S A; 2004 Jun; 101(24):9051-6. PubMed ID: 15184663
[TBL] [Abstract][Full Text] [Related]
9. Targeted apoptosis activation with GrB/scFvMEL modulates melanoma growth, metastatic spread, chemosensitivity, and radiosensitivity.
Liu Y; Zhang W; Niu T; Cheung LH; Munshi A; Meyn RE; Rosenblum MG
Neoplasia; 2006 Feb; 8(2):125-35. PubMed ID: 16611405
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
Cao S; McGuire JJ; Rustum YM
Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100
[TBL] [Abstract][Full Text] [Related]
11. An antimelanoma immunotoxin containing recombinant human tumor necrosis factor: tissue disposition, pharmacokinetic, and therapeutic studies in xenograft models.
Rosenblum MG; Cheung L; Mujoo K; Murray JL
Cancer Immunol Immunother; 1995 May; 40(5):322-8. PubMed ID: 7600565
[TBL] [Abstract][Full Text] [Related]
12. In vivo targeting of malignant melanoma by 125Iodine- and 99mTechnetium-labeled single-chain Fv fragments against high molecular weight melanoma-associated antigen.
Kang N; Hamilton S; Odili J; Wilson G; Kupsch J
Clin Cancer Res; 2000 Dec; 6(12):4921-31. PubMed ID: 11156253
[TBL] [Abstract][Full Text] [Related]
13. Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct.
Pavlinkova G; Booth BJ; Batra SK; Colcher D
Clin Cancer Res; 1999 Sep; 5(9):2613-9. PubMed ID: 10499640
[TBL] [Abstract][Full Text] [Related]
14. Antitumor efficacy of the scFv-based fusion protein and its enediyne-energized analogue directed against epidermal growth factor receptor.
Sheng W; Shang Y; Miao Q; Li Y; Zhen Y
Anticancer Drugs; 2012 Apr; 23(4):406-16. PubMed ID: 22205154
[TBL] [Abstract][Full Text] [Related]
15. Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB.
Pollack VA; Alvarez E; Tse KF; Torgov MY; Xie S; Shenoy SG; MacDougall JR; Arrol S; Zhong H; Gerwien RW; Hahne WF; Senter PD; Jeffers ME; Lichenstein HS; LaRochelle WJ
Cancer Chemother Pharmacol; 2007 Aug; 60(3):423-35. PubMed ID: 17541593
[TBL] [Abstract][Full Text] [Related]
16. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
17. Lack of antitumour activity of human recombinant tumour necrosis factor-alpha, alone or in combination with melphalan in a nude mouse human melanoma xenograft system.
Furrer M; Altermatt HJ; Ris HB; Althaus U; Rüegg C; Liénard D; Lejeune FJ
Melanoma Res; 1997 Aug; 7 Suppl 2():S43-9. PubMed ID: 9578416
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral vaccination of adenoviruses expressing fusion protein RM4/tumor necrosis factor (TNF)-alpha induces significant tumor regression.
Wright P; Zheng C; Moyana T; Xiang J
Cancer Gene Ther; 1998; 5(6):371-9. PubMed ID: 9917092
[TBL] [Abstract][Full Text] [Related]
19. Targeted delivery of human pro-apoptotic enzymes to tumor cells: In vitro studies describing a novel class of recombinant highly cytotoxic agents.
Liu Y; Cheung LH; Hittelman WN; Rosenblum MG
Mol Cancer Ther; 2003 Dec; 2(12):1341-50. PubMed ID: 14707275
[TBL] [Abstract][Full Text] [Related]
20. Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin.
Rosenblum MG; Cheung LH; Liu Y; Marks JW
Cancer Res; 2003 Jul; 63(14):3995-4002. PubMed ID: 12873997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
